Alercell

A word from the founder

Watch Video

A word from the founder

Watch Video

A word from the founder

Watch Video

A word from the founder

Watch Video

Innovative Genomic

approach

Innovative Genomic approach

Alercell is utilizing advancements in DNA sequencing to make it faster and more affordable for patients to gain insights into their genetic codes. This approach enables a deeper understanding of how genetic alterations contribute to diseases like cancer, positioning Alercell at the forefront of innovative genetic solutions in the fight against these challenges.

Lena S1 Test

LENA Q51®

Alercell is committed to revolutionizing early detection through advanced DNA sequencing techniques. By identifying cancer at its earliest stages, Alercell aims to assist patients in achieving better outcomes, potentially even preventing the progression of the disease entirely.

Service

Early Diagnostics

Alercell specializes in two primary types of cancer:

Leukemia and Non-Small Cell Lung Cancer (NSCLC).

Our approach enables a deeper understanding of how genetic alterations contribute to diseases like cancer

Lena S1 Test

DNA methylation, a critical epigenetic modification, plays a key role in addressing the challenge of early lung cancer diagnosis. Changes in methylation patterns serve as important indicators of tumorigenesis, making methylation analysis a valuable tool for early detection. Early diagnosis is particularly vital for improving outcomes in cases of Non Small Cell Lung Cancer (NSCLC), known for its high fatality rates due to rapid progression.

Visit LENA

Lena S1 Test

Visit Lena

LENA Q51®

The LENA Q51® by Alercell represents a major breakthrough in leukemia detection, identifying 55 gene mutations—far surpassing the 2-gene tests available until 2022. Using a qPCR machine, it delivers results from a simple blood test in under 3 hours, compared to the traditional 3–6 weeks involving blood tests, bone marrow biopsies, and subjective cytology.